|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||26.95 / 55.00|
The most recent short interest data was recently released for the 10/31/2018 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 5.07 "days to cover" versus the median component at 4.44.
In recent trading, shares of Pacira Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $46.31, changing hands for $47.40/share.
In recent trading, shares of Pacira Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $46.08, changing hands for $47.15/share.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANDE, BPI, CORE, ECHO, EPAY, FRD, HTBI, LAWS, MCY, MEDP, NMFC, NTES, PCRX, SCHL, SLG, SU, SWIR Downgrades: AKAM, AXU, DFRG, FFWM, IAG, IVC, MHK, RGNX, SRE, TARO, TWNK, UNFI, VECO Initiations: CGBD, SMHI, WTTR Read on to get TheStreet Quant Ratings' detailed report:
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the February 2019 expiration.
MEDNAX, Inc. (NYSE:MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira...
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the June 15th expiration.
Continuous quality improvement project aims to optimize patient outcomes after hernia repair
Company working with FDA toward April 6, 2018 PDUFA date
Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the March 16th expiration.
Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals
Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.
Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals
Expanded roles reflect key accomplishments and demonstrated leadership
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2018 expiration.
Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.